Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03973840 · ClinicalTrials.gov registry record · Phase 1
Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes
A Phase 1 study of Hypogonadism, Male, sponsored by Clarus Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03973840: Completed Phase 1 study of Hypogonadism, Male, sponsored by Clarus Therapeutics.
NCT03973840 is a Phase 1 study of Hypogonadism, Male that has completed, run by Clarus Therapeutics. The registered enrollment target is 13 participants, below the 111-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03973840, a Phase 1 study of Hypogonadism, Male, has completed, sponsored by Clarus Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation
Primary Outcome
To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation
Conditions Studied
Interventions
- DRUG Testosterone Undecanoate
Study Locations (1)
Illinois
- Clarus Therapeutics, Inc - Northbrook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-07-15 |
| Est. Completion | 2018-07-31 |
| Phase | Phase 1 |
What the finished NCT03973840 record still lists
NCT03973840 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 111-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Hypogonadism, Male appearing as the primary indexed condition, and to 1 intervention - of which Testosterone Undecanoate is the first listed.
NCT03973840 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03973840 about?
NCT03973840 is a clinical study titled "Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes". To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation
What is the current status of trial NCT03973840?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2018-07-15. Estimated completion is 2018-07-31.
What conditions does trial NCT03973840 study?
This clinical trial studies the following conditions: Hypogonadism, Male.
What interventions are being tested in trial NCT03973840?
The interventions under investigation include: Testosterone Undecanoate (DRUG).
Who is sponsoring clinical trial NCT03973840?
This trial is sponsored by Clarus Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03973840 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism, Male
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03973840's enrollment target sits among peer trials
13 13th of 12 the lowest of 12 other Hypogonadism, Male trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypogonadism, Male trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation
ACTIVE NOT RECRUITING · Phase 1
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
-
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
RECRUITING · Phase 2
-
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
RECRUITING · Phase 3
-
Testosterone Treatment in Men with Chronic Kidney Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI